PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 15, 2002European Heart Journal601 citationsOpen Access

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)

View Full Paper
VMV.S. Moiseyev

Structured PICO

Does levosimendan reduce worsening heart failure and death in patients with left ventricular failure due to an acute myocardial infarction?

P
Population
Patients with left ventricular failure due to an acute myocardial infarction
I
Intervention
Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1)
C
Comparator
Placebo
O
Outcome
Worsening heart failure and deathhard clinical

Levosimendan is safe and reduces the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.

Abstract

s Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1) did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

V.S. Moiseyev (2002) studied this question.

synapsesocial.com/papers/69d8fc462c87b79b92d18a93https://doi.org/10.1053/euhj.2001.3158
Ask AI
Helpful
Bookmark
Share
View Full Paper